Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC)

Inclusion Criteria: * 1、Written informed consent * 2、18-70 years old * 3、Adequate organ function and ECOG of 0 \~1 * 4、Without systemic therapy at the time of enrollment * 5、FIGO 2018 stage IB3, IIA2, or IIIC1r * 6、Histologically confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix * 7、Measurable lesions could be defined by RECIST v1.1 * 8、Willing to get blood/ tumor tissue tested * 9、Patients who observed the rules about the scheduled visit, study schedule, and medical examination * 10、The function of major organs is normal, and the following criteria are met: * 10.1 Blood routine examination must meet: (no blood transfusion within 14 days) Hb≥90g/L: ANC≥1.5x10\^9/L; PLT≥100x10\^9/L; * 10.2 The biochemical examination must meet the following standards BIL \< 1.5 × ULN; ALT and AST \< 2.5xULN; ALB≥ 28 g/L * 11、Patients who are willing and able to comply with visiting arrangements, treatment plans, laboratory tests, and other research procedures. Exclusion Criteria: * 1、History of other malignancies within 3 years * 2、Participate in other clinical trials at the same time * 3、Active autoimmune disease, which needs systemic therapy * 4、Uncontrolled infection, which needs systemic therapy * 5、History of allogeneic tissue/solid organ transplant * 6、Serious illness, such as severe mental disorders, cardiac disease, coagulation disorders, digestive system disease, etc * 7、Active HBV, HCV, or HIV infection * 8、Pregnant or lactating female patients * 9、Drug or alcohol abuse * 10、 Unable or unwilling to sign the informed consent